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Abstract
Objective
To explore the repertoire of glycan-speciﬁc immunoglobulin G (IgG) antibodies in treatment-
naive patients with relapsing-remitting multiple sclerosis (RRMS).
Methods
A systems-level approach combined with glycan array technologies was used to determine
speciﬁcities and binding reactivities of glycan-speciﬁc IgGs in treatment-naive patients with
RRMS compared with patients with noninﬂammatory and other inﬂammatory neurologic
diseases.
Results
We identiﬁed a unique signature of glycan-binding IgG in MS with high reactivities
to the dietary xenoglycan N-glycolylneuraminic acid (Neu5Gc) and the self-glycan
N-acetylneuraminic acid (Neu5Ac). Increased reactivities of serum IgG toward Neu5Gc
and Neu5Ac were additionally observed in an independent, treatment-naive cohort of
patients with RRMS.
Conclusion
Patients with MS show increased IgG reactivities to structurally related xenogeneic and human
neuraminic acids. The discovery of these glycan-speciﬁc epitopes as immune targets and
potential biomarkers in MS merits further investigation.
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CNS tissue damage in patients with multiple sclerosis (MS) is
mediated by both cellular and humoral immune factors, and
clonal T- and B-cell expansions within MS lesions and the
CSF suggest that the pathogenic immune responses inMS are
driven by distinct, yet incompletely deﬁned antigens.1 A
pathogenic role for antibodies is further supported by the
marked deposition of immunoglobulin G (IgG) at least in
a subset of demyelinating MS lesions.2
Glycans, polymers of glycosidically linked sugars, represent
one of the most basic cellular components of mammals and
other organisms and exist as free glycan entities as well as
being covalently attached to proteins or lipids. During the last
decade, glycans have become increasingly recognized as par-
ticipants in neural cell interactions as well as in myelin for-
mation and maintenance. Some glycan structures, attached to
proteins and expressed on the surface of neuronal and glial
cells, are speciﬁcally enriched in the mammalian brain and
have pivotal functions in nervous system development and
regeneration following CNS tissue injury.3
Despite the paradigm that glycans are T cell–independent
antigens and the observation that antibodies recognizing car-
bohydrate epitopes in chronic immune-mediated neuropathies
such as multifocal motor neuropathy are frequently immuno-
globulin M isotypes, there is evidence that CD4+ T cells are
involved in the generation of carbohydrate-speciﬁc IgG anti-
bodies following glycovaccination,4 and switched
carbohydrate-speciﬁc IgG antibodies are universally found in
humans.5,6 Furthermore, carbohydrate epitopes in conjunction
with carrier protein-derived peptides can bind major histo-
compatibility class II molecules and stimulate glycan-speciﬁc
CD4+ T cells to produce interleukins 2 and 4—cytokines es-
sential for providing T-cell help to antibody-producing B cells.7.
Here, we used a systems-level approach combined with glycan
microarray technologies to evaluate the repertoire of
carbohydrate-speciﬁc IgG antibodies in treatment-naive
patients with relapsing-remitting MS (RRMS).
Methods
Standard protocol approvals, registrations,
and patient consents
All patients included in this study were enrolled at the De-
partment of Neurology, University Hospital Basel, Switzer-
land. Institutional review board approval was granted by the
local ethics committee, and participants provided written in-
formed consent for participation. All patients with MS were
treatment naive and had relapsing-remitting disease. Serum
and CSF samples were collected and stored at −80°C fol-
lowing standardized procedures.
Glycan microarray
IgG derived from serum and CSF samples were puriﬁed using
Protein G Sepharose 4 Fast Flow (GE Healthcare, Opﬁkon,
Switzerland) according to the manufacturer’s instruction, di-
alyzed in phosphate-buﬀered saline (PBS) (Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland), and sterilized by 0.2 μM
ﬁltration. Acrylamide gel electrophoresis, Coomassie stain-
ings, and immunoblots were performed to test IgG integrity
and purity.8 Puriﬁed IgGs derived from patients with MS,
noninﬂammatory neurologic diseases (NIND), and other
inﬂammatory neurological diseases (OIND) were pooled.
Pooled samples were adjusted to similar concentrations of
IgG molecules as determined by photometry (Nano-
Drop1000; Thermo Scientiﬁc, Basel, Switzerland), sub-
sequently screened for carbohydrate recognition on the
Consortium for Functional Glycomics (CFG) array version
5.3, and detected at 50 μg/mL using the anti-human IgGmAb
clone HP-6043-Biot (5 μg/mL) coupled to streptavidin-
Alexa633 (Invitrogen, Basel, Switzerland). Antibody binding
was quantiﬁed as relative ﬂuorescence unit (RFU), and the
obtained data were evaluated using a systems biology ap-
proach, as described in reference 5.
Bio-Plex assay
The Bio-Plex glycan suspension assay was performed as pre-
viously described.6 Brieﬂy, end-biotinylated glycopolymers
(Laboratory of Carbohydrate Chemistry, Shemyakin-
Ovchinnikov Institute of Bioorganic Chemistry, Russian
Academy of Sciences, Moscow, Russian Federation) were
coupled to ﬂuorescent carboxylated beads with a distinct ratio
of red and infrared ﬂuorescent dyes (Bio-Rad Laboratories
Inc., Hercules, CA). Antibody diluent (PBS-1% bovine serum
albumin; Sigma-Aldrich Chemie GmbH) incorporating 2,000
beads of each region/well (50 μL/well) was added to a 96-well
multiscreen HTS ﬁlter plate (Millipore Corp., Billerica, MA)
previously soaked with 100 μL of antibody diluent for 5
minutes. The plate was washed twice with 100 μL washing
buﬀer (PBS-0.02% Tween 20) using a vacuummanifold (Bio-
Rad Laboratories Inc.). Human serum samples were added to
wells (in antibody diluent 1:20 [50 μL/well]) and incubated
on a shaker for 1 hour at room temperature (RT) in the dark.
After incubation, the plate was washed 3 times with washing
buﬀer. Secondary antibodies (R-PE-conjugated goat anti-
human IgG H + L; Southern Biotechnology Associates Inc.,
Birmingham, AL, 25 ng/well) were added and incubated on
a shaker for 1 hour at RT in the dark. The plate was washed 3
Glossary
CFG = Consortium for Functional Glycomics; IgG = immunoglobulin G; NCAM = neural cell adhesion molecule; Neu5Ac =
N-acetylneuraminic acid;Neu5Gc = N-glycolylneuraminic acid;NIND = noninﬂammatory neurologic diseases;OIND = other
inﬂammatory neurologic diseases; PSA = α(2–8)polysialic acid; RFU = relative ﬂuorescence unit; RT = room temperature;
RRMS = relapsing-remitting MS.
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times with washing buﬀer, and beads were resuspended and
shaken vigorously for 30 seconds in 100 μL of antibody dil-
uent. The plate was analyzed on the Bio-Plex array reader,
with which data were acquired in real time, analyzing 50 beads
by their median ﬂuorescence intensity using Bio-Plex Man-
ager 6.1 software (Bio-Rad Laboratories Inc.).
Statistical analysis
Pearson correlation matrix, heatmap, and hierarchical clus-
tering were performed using the package gplots from “R”
(The R Foundation for Statistical Computing, version 3.0.2
[rdrr.io/cran/gplots/]). For correlation analysis and heatmap
construction, negative values were set to zero. To exclude the
observations that markedly deviate from the rest of the data,
outlier exclusion was performed via the robust regression and
outlier removal method (Q = 1%). Statistical signiﬁcance of
the results was reported using 1-way analysis of variance,
followed by the Tukey multiple comparison test. A p value
<0.05 was considered statistically signiﬁcant. The asterisks
depicted in the ﬁgures translate into the following grouping:
*p < 0.05, **p < 0.01,***p < 0.001. All quantitative analyses
were performed with GraphPad Prism v5.0a or 6.0c for Mac
OSX (GraphPad Software, Inc., San Diego, CA).
Data availability
Any data not published within the article will be shared by
request from any qualiﬁed investigator.
Results
Glycan array analysis indicates unique anti-
carbohydrate IgG repertoire in MS
Glycan array technology, a powerful tool to study protein-
carbohydrate interactions on a large scale, has recently been
used to examine glycan-binding proﬁles of IgG from healthy
donors.5 To interrogate the anti-carbohydrate IgG repertoire
in patients with MS, we ﬁrst puriﬁed and pooled IgG from
serum and CSF samples derived from 25 treatment-naive
patients with RRMS and 30 patients with NIND matched by
age and sex (table). Pooled IgG samples were normalized to
concentrations of 50 μg/mL5 and screened for binding to 600
distinct glycans using the CFG glycan array version 5.3. Hi-
erarchical dendrogrammed clustering analysis was performed
to compute a reactivity matrix of IgG preparations based on
sample RFU values,5 as shown in ﬁgure 1A. The reactivity
matrix indicated that antibody repertoires between patients
with MS and NIND were distinct for at least certain glycans
(ﬁgure 1A). A relatively close relationship between glycan
recognition patterns of serum and CSF IgG was observed for
patients with MS (r = 0.81) and NIND (r = 0.86), re-
spectively. The repertoire diﬀerences between both cohorts
were conﬁrmed by Pearson correlation (ﬁgure 1B) and radial
dendrogram computation (ﬁgure 1C). Since the chemical
structure of the terminal carbohydrate moiety has been linked
to immunogenicity and hence the IgG immune proﬁle in
healthy individuals,5 we next determined IgG reactivities to
glycans with speciﬁc terminal carbohydrates. Although most
terminal glycan structures were recognized by both patients
with MS and NIND, high reactivities to individual terminal
N-acetylneuraminic acid (Neu5Ac) epitopes and the struc-
turally related N-glycolylneuraminic acid (Neu5Gc) were
exclusively observed in patients with MS (ﬁgure 1D).
Increased IgG reactivity to xenogeneic and
human neuraminic acids in MS
Terminal glycan recognition was further evaluated in individual
serum and CSF samples derived from our MS discovery and
NIND cohorts using an independent bead-based multiplex
glycan suspension assay. To assess whether IgG reactivities are
largely determined by inﬂammation ormore speciﬁcally related
to MS, we additionally recruited a cohort of 22 patients with
OIND (table). Based on the results obtained with the CFG
glycan array with exclusively increased reactivities to distinct
Neu5Ac and Neu5Gc epitopes in MS, we speciﬁcally de-
termined IgG responses to (Neu5Ac2-8)3, an α(2–8)-linked
homooligomer of Neu5Ac, hereafter termed α(2–8)Neu5Ac,
and to the Neu5Gc epitope Neu5Gcα2-3Galβ1-3GlcNAcβ,
hereafter termed α(2–3)Neu5Gc. As a reference, we addi-
tionally assessed IgG responses to the α(1–3)-linked galactose
epitope (Galα1-3Galβ1-4GlcNAcβ) because anti-Gal-α anti-
bodies are frequently detectable in immunocompetent indi-
viduals and produced throughout life as a result of continuous
antigenic stimulation by carbohydrate antigens on gastroin-
testinal bacteria of the normal ﬂora.9
Antibody reactivities toward neuraminic acid epitopes were
signiﬁcantly increased in patients with MS compared with
patients with NIND and OIND. Both serum and CSF IgG
reactivities toward α(2–8)Neu5Ac and CSF IgG responses
toward α(2–3)Neu5Gc were signiﬁcantly elevated in patients
with MS (ﬁgure 2, A and B). In contrast, IgG reactivities to the
Gal-α epitope were unchanged in patients withMS (ﬁgure 2C).
To validate increased immunoreactivity to neuraminic acid
epitopes in MS, we additionally recruited an independent
second cohort of treatment-naive patients with RRMS (table)
and reperformed the Bio-Plex assay. In these patients (MS
cohort II), serum IgG reactivities to both α(2–8)Neu5Ac and
α(2–3)Neu5Gc were increased compared with NIND and
OIND, whereas CSF IgG reactivities did not diﬀer signiﬁcantly
(ﬁgure 2, D and E), indicating a systemically increased immune
response to both epitopes.We observed a strong overlap of IgG
reactivities to Neu5Ac and Neu5Gc in individual patients. In
cohort I, 73% and 92% of patients with MS with above-median
anti-Neu5Ac levels also show above-median anti-Neu5Gc lev-
els in serum and CSF samples, respectively. In cohort II, 90%
and 90% of patients with MS with above-median anti-Neu5Ac
levels also show above-median anti-Neu5Gc levels in serum
and CSF samples, respectively. Patients with high IgG reac-
tivities (above median) did not diﬀer from patients with low
(below median) IgG reactivities to Neu5Ac and Neu5Gc
epitopes in clinical disease severity as determined by the
expanded disability status score and disease activity as deﬁned
by having a relapse or being in remission during the time of
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blood and CSF sampling (ﬁgure 3). Altogether, these data
demonstrate that the anti-carbohydrate IgG repertoire in
patients with MS contains elevated reactivities toward both
α(2–8)Neu5Ac and α(2–3)Neu5Gc neuraminic acids.
Discussion
Our study is the ﬁrst investigation to systematically in-
terrogate the carbohydrate-speciﬁc IgG repertoire in patients
with MS. We found that treatment-naive patients with early
MS diﬀer from patients with NIND and OIND in their rec-
ognition of terminal carbohydrate moieties with increased
reactivities toward the neuraminic acid α(2–8)Neu5Ac and
the structurally related α(2–3)Neu5Gc.
The α(2–8)Neu5Ac oligomers constitute the building blocks
of α(2–8)polysialic acid (PSA), whose major carrier in ver-
tebrates is the neural cell adhesion molecule (NCAM). PSA is
widely expressed in the developing brain, absent in the adult
Table Demographic, clinical, and CSF characteristics of patient cohorts
Early MS
discovery
cohort
Early MS
validation
cohort NIND OIND
N 25 25 30 22
Female 18 21 22 7
Age (mean, median, SD) 36.1, 35.5, 10.6 34.8, 32.5, 11.7 43.9, 44.7, 13.9 55.2, 58.9, 18.7
Age range (y) 20.8–61.8 19.1–70.6 16.8–73.3 19.9–80.6
Last EDSS score before
spinal tap (mean,
median, SD),
2, 2, 0.9 1.96, 2, 0.9 NA NA
EDSS score (range) 0–4 0–3.5 NA NA
%Treatment naive 100 100 NA NA
Status at the time point
of spinal tap: (%relapse/
%stable)
60/40 64/36 NA NA
CSF leukocytes/μL
(mean, median, SD)
7.1, 5, 7 5.9, 4.6, 6.1 1.6, 1, 1.5 47.8, 34.4, 39.8
CSF total protein mg/L
(mean, median, SD)
384, 378, 138 336.6, 328, 86.1 362.1, 337.5, 116.5 892, 594, 894.2
IgG index (mean,
median, SD)
1.1, 0.9, 0.5 1.03, 0.8, 0.6 0.5, 0.5, 0.05 0.6, 0.6, 0.2
CSF OCB+
(n = positive/
n = negative/
n = borderline)
0/25/0 0/25/0 0/30/0 8/12/2
CSF Reiber IgG% (mean,
median, SD)
28.2, 31, 24.8 24.3, 17, 24.99 0, 0, 0 4.7, 0, 11
CSF Reiber IgM% (mean,
median, SD)
13.1, 0, 23.4 8.2, 0, 19.1 0.4, 0, 2 16.1, 0, 29
CSF Reiber IgA% (mean,
median, SD)
3.7, 0, 12.8 1.7, 0, 8.5 0, 0, 0 8.9, 0, 21
Clinical diagnoses Early MS
(n = 25)
Early MS
(n = 25)
Tension-type headache (n = 11), migraine
and other headache entities (n = 3),
symptoms related to paresthesia,
hypesthesia, and pain (n = 5), seizure
associated (n = 3), somatoform/
psychogenic disorder (n = 2),
neuropsychological disorder/depression
(n = 2), obstructive sleep apnea (n = 1),
vascular leukoencephalopathy
(n = 1), central vestibular disturbance (n =
1), and pseudotumor cerebri (n = 1)
Viral (meningo)encephalitis (n = 6),
neuroborreliosis (n = 4), (meningo)
encephalitis of unknown etiology (n = 4),
eosinophilic encephalitis (n = 1), giant cell
arteritis (n = 1), zoster ophthalmicus (n =
1), oligoneuritis cranialis (n = 1),
tuberculous meningoencephalitis (n = 1),
varicella zoster–associated polyradiculitis
(n = 1), neurosarcoidosis (n = 1), and
meningoradiculitis (n = 1)
Abbreviations: EDSS = expanded disability status score; IgG = immunoglobulin G; IgM = immunoglobulin M; NA = not applicable; NIND = noninflammatory
neurologic diseases; OCB = oligoclonal bands; OIND = other inflammatory neurologic diseases.
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brain, but reexpressed upon CNS injury during which it
supports repair mechanisms including cell migration, axon
guidance, and synaptic plasticity.3,10 Targeted overexpression
of PSA or administration of PSA mimetics improves neuronal
regeneration and functional recovery upon spinal cord
injuries.11,12 In MS lesions, PSA-NCAM is reexpressed on
demyelinated axons but absent from myelinated axons of the
periplaque or normal-appearing white matter, possibly in an
attempt to achieve neuroprotection following demyelinating
injury.10 We infer from these data that IgG speciﬁc for α(2–8)
Neu5Ac oligomers could also bind to NCAM decorated with
α(2–8)Neu5Ac within MS plaques.
The structurally almost identical andNeu5Ac derivativeNeu5Gc
cannot be synthesized by humans due to a loss-of-function
mutations in the gene encoding the sialic acid–modifying en-
zyme cytidine monophosphate-N-acetylneuraminic acid hy-
droxylase but is found in most nonhuman mammals and is
enriched in red meat from livestock (beef, pork, and lamb).13
Despite the absence of endogenously produced Neu5Gc, ex-
perimental studies in humans and inCmah−/−mice revealed that
dietary Neu5Gc can become incorporated into tissues in trace
amounts, essentially making Neu5Gc a dietary “xeno-auto-
antigen”, and transfer of Neu5Gc-speciﬁc polyclonal IgG anti-
bodies to Cmah−/− mice fed with Neu5Gc was shown to
promote systemic inﬂammation.13–16 Based on the aforemen-
tioned studies, it has been proposed that anti-Neu5Gc antibodies
may contribute to the development of various human chronic
inﬂammatory diseases that are not seen in great apes, such as
MS.15,17,18 Although healthy diets have been associated with
a reduced risk to develop MS,19 studies investigating red meat
consumption and risk of MS have been inconclusive so far,20–22
and it is unknown whether and to which extend dietary Neu5Gc
can be incorporated into tissues including the CNS. However,
given the structural similarity betweenNeu5Gc andNeu5Ac and
the large overlap of reactivities toward both carbohydrate epit-
opes in individual patients, systemically increased IgG responses
to both terminal glycan structures in patients with MS might
partly result from cross-reactive antibody species23: exposure to
a dietary xenoantigen expressed in peripheral tissues could elicit
immune reactivity to a self-antigen, reexpressed upon myelin
injury in MS lesions. This scenario does not necessarily depend
on intrathecal production or enhanced reactivities of glycan-
speciﬁc CSF IgG.
Figure 1 Recognition of carbohydrate structures in glycan array version 5.3 by sera and CSF of patients with MS and NIND
(A) Heatmap of glycan-binding reactivity, clustered by dendrogram algorithm. Columns represent the reactivity of each specific glycan (n = 600) at an
immunoglobulin G concentration of 50 μg/mL, and rows represent the immune profile for each patient subgroup (MS, n = 25; NIND, n = 30). (B) Pearson
correlation comparison of glycan recognition in sera and CSF among patients. (C) Circlized dendrogram for recognition of carbohydrate antigens based on
RFU. Clusters based on recognition similarity are shown in the same color. (D) Recognition of specific terminal carbohydrate moieties by sera or CSF from
patients with MS and NIND. Neu5Ac = N-acetylneuraminic acid; Neu5Gc = N-glycolylneuraminic acid; NIND = noninflammatory neurologic disease; RFU =
relative fluorescence unit.
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Limitations of our study include the small size of the cohorts
investigated. Although increased IgG reactivities to α(2–8)
Neu5Ac and α(2–3)Neu5Gc were conﬁrmed in an
independent cohort of patients with MS, our ﬁndings clearly
require validation in larger independent studies. Patients with
OIND did not diﬀer from patients with NIND in their serum
Figure 2 Increased reactivity to sialic acid–terminated glycan epitopes Neu5Ac and Neu5Gc in patients with MS
Recognition of α(2–8)Neu5Ac, α(2–3)Neu5Gc, andGalα1-3Galβ1-4GlcNAcβ carbohydrate structures by sera and CSF. patients withMS fromdiscovery cohort I
(A–C) and independent cohort II (D and E) compared with patients with other neurologic diseases NIND and OIND as screened by suspension array. Each dot
represents an individual patient. Bar represents median. Significant values are reported using 1-way ANOVA, followed by Tukey multiple comparison test.
*p < 0.05; **p < 0.01, ***p < 0.001. ANOVA = analysis of variance; Neu5Ac = N-acetylneuraminic acid; Neu5Gc = N-glycolylneuraminic acid; NIND =
noninflammatory neurologic disease; OIND = other inflammatory neurologic disease; RFU = relative fluorescence unit.
Figure 3High vs low IgG reactivities to Neu5Ac and Neu5Gc epitopes in relation to MS clinical disease severity and activity
Patients with MS were stratified by means of their high IgG reactivities to Neu5Ac and Neu5Gc epitopes (above median vs below median). (A) Above- and
below-median groups were compared with regard to the EDSS score and (B) clinical disease activity as defined by having a relapse or being in remission
during the time of blood and CSF sampling. Each dot represents an individual patient. SEM is depicted. Statistical analysis was performed via the (A) Mann-
Whitney test and (B) Fisher exact test. EDSS = expanded disability status score; IgG = immunoglobulin G; Neu5Ac = N-acetylneuraminic acid; Neu5Gc = N-
glycolylneuraminic acid; ns = non significant; SEM = standard error of the mean.
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and CSF immunoreactivity proﬁle toward Neu5Ac and
Neu5Gc. However, we cannot exclude the possibility that the
increased response to the aforementioned epitopes might
result from polyclonal B lineage cell stimulation driven by
chronic inﬂammation without being speciﬁc for MS. Second,
the functional relevance of our ﬁndings is hypothetical, and
longitudinal studies are required to assess whether immune
reactivities to Neu5Ac and Neu5Gc are associated with MS
disease activity and progression. Whether IgG speciﬁc for
neuraminic acid–containing epitopes are germline conﬁgured
or selected for high aﬃnity during germinal center reactions in
patients with MS and healthy individuals requires further in-
vestigation. Our ﬁndings, therefore, should provide incentive
to conduct larger prospective and experimental investigations
to examine the functional role of terminal glycan structures as
immune targets and potential biomarkers in MS.
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